OncologyOnline.net

Oncology Xagena

Xagena Mappa
Medical Meeting
Gastrobase.it
Xagena Salute

Search results for "Renal cell carcinoma"

An interim analysis of a Phase III study of Avastin ( Bevacizumab ) in combination with Paclitaxel and Carboplatin in advanced, non-small cell lung cancer ( NSCLC ) met its primary efficacy endpoint ...


An investigational new drug Sutent ( Sunitinib ) more than doubled survival and significantly reduced tumor growth and spread in patients with Imatinib-resistant gastrointestinal stromal tumors ( GIS ...


Researchers at the Massachusetts General Hospital ( MGH ) have shown that radiofrequency ablation ( RFA ) – a minimally invasive way of destroying tissue – is an effective, longlasting treatment for s ...


Researchers at the Mayo Clinic Cancer Center report that Imatinib ( Glivec, Gleevec ), the drug used to treat patients with gastrointestinal stromal cancers ( GISTs ), is not likely to be effective fo ...


Axel Ullrich, at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a tumour slows down its growth ...


A phase III clinical trial has shown that Lapatinib ( Tykerb ) slows cancer growth and improves survival in a subset of patients with an advanced renal cell carcinoma ( RCC ) that continued to grow de ...


A study suggests that Sunitinib ( Sutent ) is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options. The study is published ...


Sunitinib ( Sutent ) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma ...


The results of a phase III, randomized clinical study involving patients with advanced renal cell carcinoma and poor prognostic features show Temsirolimus ( Torisel ) improved overall survival when co ...


Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-val ...


Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...


Older and younger patients with renal cancer derive similar benefit from Sorafenib ( Nexavar ) therapy and tolerate the drug equally well. Although the risk of being diagnosed with cancer increa ...


Treatment with Everolimus ( Certican ) prolongs progression-free survival relative to placebo in patients with metastatic kidney cancer ( renal cell carcinoma ) who have experienced treatment failur ...


Treatment with Everolimus ( Afinitor ) prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma who have experienced treatment failure on other regimens. ...


Sunitinib ( Sutent ) prolongs progression-free and overall survival, and is safe and well tolerated in advanced kidney cancer ( metastatic renal cell carcinoma ) patients with a poor prognosis such as ...